Publications by authors named "Karsten Denner"

Claim this Profile
D
Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12.
Timothy A Lewis, Manuel Ellermann, Charlotte Kopitz, Martin Lange, Luc de Waal, Karsten Denner

ACS Med Chem Lett· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
Stefanie Reif, Marcus-Hillert Schultze-Mosgau, Anna Engelen, Isabel Piel, Karsten Denner

Eur J Drug Metab Pharmacokinet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IRAK4 Inhibitors (Zabedosertib) and .
Ulrich Bothe, Judith Günther, Reinhard Nubbemeyer, Holger Siebeneicher, Sven Ring, Karsten Denner

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Ulrich Lücking, Dirk Kosemund, Niels Böhnke, Philip Lienau, Gerhard Siemeister, Karsten Denner

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Päivi Taavitsainen, Olaf Prien, Marja Kähkönen, Michael Niehues, Timo Korjamo, Karsten Denner

Drug Metab Dispos· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.
Ulrich Lücking, Lars Wortmann, Antje M Wengner, Julien Lefranc, Philip Lienau, Karsten Denner

J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Christian Zurth, Mikko Koskinen, Robert Fricke, Olaf Prien, Timo Korjamo, Karsten Denner

Eur J Drug Metab Pharmacokinet· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Karsten Denner

ChemMedChem· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro.
Anne Christiansen, Thomas Backensfeld, Karsten Denner, Werner Weitschies

Eur J Pharm Biopharm· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients.
Lorenz M Jost, Hans-Peter Gschwind, Tarja Jalava, Yongyu Wang, Clemens Guenther, Karsten Denner

Drug Metab Dispos· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The protein-tyrosine phosphatase DEP-1 modulates growth factor-stimulated cell migration and cell-matrix adhesion.
Enrico Jandt, Karsten Denner, Marina Kovalenko, Arne Ostman, Frank-D Böhmer

Oncogene· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis